Preparation of medicinal carbon tablets by modified wet compression method

Background: Although medicinal carbon (MC) is useful to treat intoxications caused by orally taken toxic chemicals or toxins, high dose of MC is a burden on patients and sticks to oral mucosa or throat. A tablet dosage form of MC is useful to solve such problems. Fast-disintegration, adequate hardness, and quick and high-adsorption potential are required for MC tablets. Method: A modified wet compression method using carboxymethylcellulose sodium (CMC-Na) solution as binder solution was newly developed. Croscarmellose sodium (CC-Na) was used as a disintegration agent. MC granules, binder solution, and MC granules were placed in the cylinder in that order, and the resultant mass was compressed. The obtained tablets were examined for hardness, disintegration rate, and acetaminophen adsorption profiles. Results: The tablets, produced with MC granules containing CMC-Na and CC-Na at 10% each and using 280?μL of 2.5% (w/w) CMC-Na binder solution in compression, showed adequate hardness (more than 4?kg), short disintegration time (less than 6 min), and almost the same acetaminophen adsorption profile as intact MC powder. Conclusion: The modified wet compression with CMC-Na and CC-Na is suggested to be useful to obtain MC tablets with good quality.     

HPLC法测定富马酸喹硫平片有关物质

建立了高效液相色谱（HPLC）法测定富马酸喹硫平片的有关物质的方法。色谱柱为依利特（ODS 5μm,4.6mm×250mm）,以甲醇-水-三乙胺（670∶330∶4）用磷酸调节pH值为6.8为流动相,流速为1.0mL/min,检测波长为289nm。该方法简便、准确、专属性强,可用于富马酸喹硫平片中有关物质的测定。     

安吉白茶含片的制作及其抗氧化活性评价

经过筛选配方和优化工艺,采用湿颗粒法制备安吉白茶含片并进行质量评价;采用清除DPPH自由基、ABTS+自由基,测定亚铁离子螯合活性和还原力,评价其抗氧化活性。结果表明,安吉白茶提取物、蔗糖、柠檬酸、糊精等对含片的质量有较大影响,最佳配方为90%乙醇做湿润剂,成品含5%安吉白茶提取物、40%蔗糖、20%麦芽糊精、1.6%柠檬酸、3%VC、5%牛磺酸、25.4%甘露醇和0.6%硬脂酸镁。该含片清除DPPH自由基、ABTS+自由基的IC50分别为48.74、43.32μg/mL,对亚铁离子的半螯合浓度为773.60μg/mL,还原力为0.97μmol/mg。该含片口感好,有安吉白茶风味,表面光滑美观,硬度、崩析性好,具有良好的抗氧化活性。     

金银花泡腾饮料片加工工艺的研究

以崩解时限、口感、澄明度等为考察指标,通过单因素实验及正交实验筛选金银花泡腾饮料片配方。实验表明,最佳配方为:金银花浸膏粉质量分数为40%,崩解剂用量为27%(由PEG6000包裹的碳酸氢钠与柠檬酸组成,重量比为1.3:1),32%乳糖为稀释剂,1%PEG6000为润滑剂。其中制粒时和制粒后加入的崩解剂比例为5:4。本法工艺可行、重现性好,所制得金银花泡腾片崩解性好,硬度符合要求,崩解后所形成的饮料澄明、口感好。     

人参蓝莓口嚼片的研制

精选白参经过超声波提取,得到人参提取物。蓝莓经过榨汁、喷雾干燥制成蓝莓果汁粉。以人参提取物和蓝莓果汁粉为主要原料,淀粉、木糖醇等为辅料,以40%乙醇作为润湿剂,经压片而制成的一种新型口嚼片。通过单因素和正交试验,确定最佳工艺条件和配方。结果表明,人参提取物添加量为15%、蓝莓果汁粉添加量35%、淀粉添加量为20%、40%乙醇添加量为40%。     

Spatially resolved characteristics of pharmaceutical sprays

Spatially resolved drop size, velocity, and volume flux data for five different spray coating guns were described in this study. Such spatially resolved measurements show how sprays respond to changes in operating conditions and gun design in ways that less complete measurements can not provide. Data for instance, allow us to recognize the unique drop size distribution of one of the sprays tested, which ultimately was an important factor in determining the dual roles of the shaping air flows: depending on drop size, viscosity, and the magnitude of the shaping air velocity, the shaping air can either pinch or induce secondary atomization to the sprays. When the former outweighs the latter, a dumbbell‐shaped spray develops; a more uniform spray results when the opposite occurs. Volume flux data from the different sprays also suggest that a more robust and consistent tablet coating process can likely be designed by utilizing multiple overlapping round sprays. © 2011 American Institute of Chemical Engineers AIChE J, 2012     

微丸压片法制备单硝酸异山梨酯缓释片

目的制备单硝酸异山梨酯微丸缓释片,考察体外释放度。方法制备单硝酸异山梨酯微丸,包衣后压制缓释片,通过考察不同包衣材料、丸芯大小、压片压力及包衣增重对缓释片体外释放度的影响,筛选并确定最佳处方。结果按优化处方制备的单硝酸异山梨酯缓释片体外释放度与市售单硝酸异山梨酯缓释片体外释放度一致。结论制备的制剂处方合理,工艺可行,体外释放度与市售片一致。     

乳酶生片中乳酸菌的分离鉴定及其增殖培养条件优化

该研究采用传统培养分离法从乳酶生片中分离乳酸菌,通过形态观察、生理生化试验及分子生物技术对其进行鉴定,并采用单因素及响应面试验对其增殖培养条件及培养基进行优化。结果表明,从乳酶生片中分离得到一株乳酸菌Y1,经鉴定为屎肠球菌（Enterococcus faecium）,其最适培养条件为初始pH 8.0,生长温度37 ℃,接种量1%,最优增殖培养基为乳糖11 g/L,乳清粉10 g/L,酵母浸粉22 g/L,硫酸镁0.28 g/L,硫酸锰0.18 g/L。用此培养基培养所得E. faecium Y1的活菌数为2.90×109 CFU/mL,比优化前活菌数提高了80.12%。     

响应面法优化复方降脂片的成型性工艺及其降脂活性

目的:优化复方降脂片的成型性工艺,并对其降脂活性进行研究。方法;采用Box-Behnken响应面法,以复方降脂片提取物为主药,以脆碎度、崩解时限及溶出度为评价指标,对主药与填充剂的比例、崩解剂的用量及乙醇的浓度为影响因素,优化复方降脂片的成型性工艺。同时采用高脂血症大鼠模型评价复方降脂片的降脂活性。结果:最优成型性工艺为:主药与辅料比例为80∶15,崩解剂用量为5%,乙醇浓度为80%。验证实验结果:各批次样品综合评分为94.01%,与预测值相对误差为1.49%,且脆碎度和崩解时限均符合药典规定;降脂活性实验:与高脂模型组的实验数据相比,复方降脂片各剂量组大鼠血清中,除高密度脂蛋白（HDL-C）外,其他指标均呈下降趋势,其中高剂量组各指标水平均呈极显著下降（P<0.01）;中剂量组AST、ALT水平呈极显著下降（P<0.01）,TC、TG及LDL-C的水平显著下降（P<0.05）,HDL-C水平增加,与模型组差异显著（P<0.05）。结论:本实验优选的成型性工艺,稳定可行,且复方降脂片降脂活性良好,本研究结果为复方降脂片的生产开发提供可靠依据。     

复方黄黛片治疗急性早幼粒细胞白血病的系统评价

目的 评价复方黄黛片( CRNTT)治疗急性早幼粒细胞白血病(APL)的疗效与安全性。方法计算机检索SinoMed、CNKI、VIP、万方、CBA、PubMed、MEDLINE、EMBASE、Cochrane图书馆临床对照试验资料库,并辅以手工检索,收集国内外公开发表的CRNIT治疗APL的随机对照试验(RCT)文献,检索年限截至201 1年3月。按纳入标准与排除标准筛选文献并评价纳入研究的质量,以完全缓解(CR)率、达CR所需时间、复发率、病死率、不良反应率等为评价指标,采用RevMan 5.1软件进行Meta分析。结果纳入6项RCT,包括391例APL患者,其中2项RCT研究目的为CRNIT与三氧化二砷(ATO)的比较,4项RCT研究目的为CRNIT与全反式维甲酸(ATRA)的比较,其中1项RCT增设CRNIT+ ATRA与ATRA的比较。达CR所需时间：CRNIT比ATRA、ATO长[加权均数差(WMD)=3.14,95％CI 0.99 ～5.29,P=0.004];头痛发生率：CRNTT低于ATRA（OR=0.10,95％CI 0.02～0.45,P=0.003）;5年无病生存率：CRNIT优于ATRA（OR= 7.22,95％CI 1.40～37.25,P=0.02）;CR率、复发率、病死率和4项不良反应指标（胃肠道症状、肝肾功能损害、皮肤损害、发热）的Meta分析结果差异无统计学意义。结论服用CRNIT达CR所需时间比ATRA、ATO长,CRNIT近期疗效与ATRA、ATO相近。服用CRNIT的5年无病生存率可能优于ATRA。